Pulmicort Generics Win a Negative for Teva, Canaccord Says

U.S. court ruling allowing generic versions of AstraZeneca’s Pulmicort asthma treatment may spur 2% reduction in Teva EPS for 3 quarters and greater hit in 2014, Canaccord Genuity analysts led by Randall Stanicky wrote in e-mailed note. *Teva likely to lose royalty back to AstraZeneca *Teva reaffirmed hold, $45 pt

Before it's here, it's on the Bloomberg Terminal.